TCS Digitally Transforms QIAGEN’s Global Research Platform to Improve User Experience with New Digital Capabilities
Tata Consultancy Services Helps QIAGEN to Increase Customer Engagement and Provide a Better User Experience with the Rearchitected GeneGlobe – Design & Analysis Hub
MUNICH | MUMBAI, February 25, 2020: Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS) a leading global IT services, consulting and business solutions organization, has transformed QIAGEN’s GeneGlobe, a genomics-based research platform for biology and biomedical researchers, to improve customer experience.
QIAGEN is a leading provider of sample to insight solutions for customers in life sciences and molecular diagnostics. To cater to the expectations of a large proportion of researchers who are digital natives, it was looking to transform its GeneGlobe research platform. The company partnered with TCS given its deep contextual knowledge, strong digital capabilities in cloud and microservices, as well as expertise in designing intuitive, customer-centric platforms.
TCS adopted a cloud-based microservices architecture and revamped the GeneGlobe platform by leveraging industry-best DevOps practices and design thinking approaches. The new platform, GeneGlobe – Design & Analysis Hub, offers an intuitive interface, helping researchers to find the right product in just three steps.
Powerful algorithms link products to biological targets, so researchers can explore and expedite decisions on products within the relevant context. Personalized dashboards and product builders are now easier to use and enable the creation of virtually any custom product for a specific research question. This transformation has helped QIAGEN to boost overall digital revenue.
“We are excited that the new GeneGlobe Design & Analysis Hub is now available and ready to provide customers with next-level experiment planning, execution and follow-up. With GeneGlobe we are offering researchers one place to navigate knowledge, tools and analyses for their specific target, saving researchers time and budget,” said Peter Rene Hesse, Head of Digitalization, QIAGEN Life Sciences Business. “The partnership with TCS helps us to drive growth and transformation aligned with our company vision of making improvements in life possible.”
“Our long-term strategic partnership with TCS has allowed us to tap into their deep contextual knowledge of the life sciences industry. This has continuously paid dividends both to the overall success of our business and, more importantly, to the experience we’re able to provide to our customers,” said Dr Thomas Schweins, Senior Vice President and Head, Life Sciences Business, QIAGEN.
“With the new intuitive, customer-centric design and scalable cloud-native architecture, QIAGEN’s platform delivers a superior user experience that will attract a new class of researchers, and accelerate and spur new research that improves lives,” said Vikas Jain, Business Head, Life Sciences, TCS. “Our ability to harness the power of digital technologies to reimagine business models and enhance customer experiences has made us the preferred transformation partner to our life sciences customers in their Business 4.0™ journeys.”
TCS partners with leading life sciences companies to enable their digital transformation journey by leveraging its Business 4.0 framework. TCS offers a full set of digital transformation services and solutions including advisory services, predictive and prescriptive analytics, genomics research, advanced platform solutions, digital content factory, digital marketing and cognitive business operations.
About Tata Consultancy Services Ltd (TCS)
Tata Consultancy Services is an IT services, consulting and business solutions organization that has been partnering with many of the world’s largest businesses in their transformation journeys for the last fifty years. TCS offers a consulting-led, cognitive powered, integrated portfolio of business, technology and engineering services and solutions. This is delivered through its unique Location Independent Agile delivery model, recognized as a benchmark of excellence in software development.
A part of the Tata group, India's largest multinational business group, TCS has over 446,000 of the world’s best-trained consultants in 46 countries. The company generated consolidated revenues of US $20.9 billion in the fiscal year ended March 31, 2019, and is listed on the BSE (formerly Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. TCS' proactive stance on climate change and award-winning work with communities across the world have earned it a place in leading sustainability indices such as the Dow Jones Sustainability Index (DJSI), MSCI Global Sustainability Index and the FTSE4Good Emerging Index. For more information, visit us at www.tcs.com.
To stay up-to-date on TCS global news, follow @TCS_News.
About QIAGEN N.V.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
TCS Media Contacts
Phone: +65 9138 4370
Australia and New Zealand
Phone: +61 422 989 682
Phone: +31 615 903387
Phone: +1 647 790 7602
Phone: +49 172 6615789
Phone: +91 22 6778 9960
Phone: +81 80 2115 0989
Phone: +569 6170 9013
Phone: +44 20 3155 2421
Phone: +1 646 313 4594